Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

LEXX Relative to the S&P 500

LEXX Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Lexaria Bioscience Corp. (NASD:LEXX) seasonal charts above shows that a Buy Date of November 10 and a Sell Date of February 3 has resulted in a geometric average return of 5.09% above the benchmark rate of the S&P 500 Total Return Index over the past 18 years. This seasonal timeframe has shown positive results compared to the benchmark in 13 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 18 years by an average of 31.12% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Lexaria Bioscience Corp’s patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

To download LEXX seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: LEXX